File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s12072-021-10213-7
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Role of serum M2BPGi levels in predicting persistence of advanced fibrosis in chronic hepatitis B virus infection
Title | Role of serum M2BPGi levels in predicting persistence of advanced fibrosis in chronic hepatitis B virus infection |
---|---|
Authors | |
Issue Date | 2021 |
Publisher | Springer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072 |
Citation | The 30th Asian Pacific Association for The Study of Liver (APASL) 2021, Virtual Meeting, Bangkok, Thailand, 4-6 February 2021. In Hepatology International, 2021, v. 15 n. Suppl. 1, p. S52-S53, abstract no. H-78 How to Cite? |
Abstract | Background: Mac-2-binding protein glycosylation isomer (M2BPGi) is a serum marker for liver fibrosis for various liver diseases including chronic hepatitis B (CHB). We aimed to evaluate its role in predicting persistence of advanced fibrosis (F3/F4) in CHB patients. Method: CHB patients with F3/F4 who were treated with nucleos(t)ide analogues (NAs) for ≥3 years with normal alanine aminotransferase and undetectable serum HBV DNA were prospectively recruited. Paired assessment with transient elastography (TE) and M2BPGi measurements were performed at baseline and 3 years. F3/F4 was defined by liver stiffness (LS) ≥9 kPa. Results: A total of 143 patients (M:F= 101:42; median age 58.7 years) were recruited and completed paired assessment. The baseline median LS and M2BPGi values were 12 (IQR: 10.5-18.2) kPa and 0.99 cut-off-index (IQR: 0.75-1.74) (COI), respectively, with 96% concordance for diagnosing F3/F4. Multivariate analysis showed that baseline M2BPGi (OR 2.128, 95% CI 1.037-4.366) and presence of central obesity (OR 4.648, 95% CI 1.742-12.402) were significantly associated with persistent F3/F4 at 3 years. Baseline M2BPGi ≥1.265 COI has 50.6% sensitivity and 79.4% specificity for predicting persistent F3/F4 at 3 years (AUROC: 0.695). Combining both the presence of central obesity and baseline M2BPGi ≥1.265 COI, 95.7% patients had persistent F3/F4. Five patients developed HCC during follow-up and were associated with bigger median relative percentage increment of serum M2BPGi compared to patients without HCC (46% vs 6.2%, P=0.038). Conclusion: Among CHB patients with F3/F4 diagnosed by TE, high serum M2BPGi was associated with persistent F3/F4 after 3 years of ongoing antiviral therapy. |
Description | Poster presentation - Hepatitis B and Hepatitis D - no. H-78 |
Persistent Identifier | http://hdl.handle.net/10722/300714 |
ISSN | 2023 Impact Factor: 5.9 2023 SCImago Journal Rankings: 1.813 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Cheung, KSM | - |
dc.contributor.author | Hui, WHR | - |
dc.contributor.author | Liu, F | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2021-06-18T14:56:00Z | - |
dc.date.available | 2021-06-18T14:56:00Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | The 30th Asian Pacific Association for The Study of Liver (APASL) 2021, Virtual Meeting, Bangkok, Thailand, 4-6 February 2021. In Hepatology International, 2021, v. 15 n. Suppl. 1, p. S52-S53, abstract no. H-78 | - |
dc.identifier.issn | 1936-0533 | - |
dc.identifier.uri | http://hdl.handle.net/10722/300714 | - |
dc.description | Poster presentation - Hepatitis B and Hepatitis D - no. H-78 | - |
dc.description.abstract | Background: Mac-2-binding protein glycosylation isomer (M2BPGi) is a serum marker for liver fibrosis for various liver diseases including chronic hepatitis B (CHB). We aimed to evaluate its role in predicting persistence of advanced fibrosis (F3/F4) in CHB patients. Method: CHB patients with F3/F4 who were treated with nucleos(t)ide analogues (NAs) for ≥3 years with normal alanine aminotransferase and undetectable serum HBV DNA were prospectively recruited. Paired assessment with transient elastography (TE) and M2BPGi measurements were performed at baseline and 3 years. F3/F4 was defined by liver stiffness (LS) ≥9 kPa. Results: A total of 143 patients (M:F= 101:42; median age 58.7 years) were recruited and completed paired assessment. The baseline median LS and M2BPGi values were 12 (IQR: 10.5-18.2) kPa and 0.99 cut-off-index (IQR: 0.75-1.74) (COI), respectively, with 96% concordance for diagnosing F3/F4. Multivariate analysis showed that baseline M2BPGi (OR 2.128, 95% CI 1.037-4.366) and presence of central obesity (OR 4.648, 95% CI 1.742-12.402) were significantly associated with persistent F3/F4 at 3 years. Baseline M2BPGi ≥1.265 COI has 50.6% sensitivity and 79.4% specificity for predicting persistent F3/F4 at 3 years (AUROC: 0.695). Combining both the presence of central obesity and baseline M2BPGi ≥1.265 COI, 95.7% patients had persistent F3/F4. Five patients developed HCC during follow-up and were associated with bigger median relative percentage increment of serum M2BPGi compared to patients without HCC (46% vs 6.2%, P=0.038). Conclusion: Among CHB patients with F3/F4 diagnosed by TE, high serum M2BPGi was associated with persistent F3/F4 after 3 years of ongoing antiviral therapy. | - |
dc.language | eng | - |
dc.publisher | Springer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072 | - |
dc.relation.ispartof | Hepatology International | - |
dc.relation.ispartof | The 30th Asian Pacific Association for the Study of Liver (APASL) Annual Meeting, 2021 | - |
dc.title | Role of serum M2BPGi levels in predicting persistence of advanced fibrosis in chronic hepatitis B virus infection | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Mak, LY: lungyi@hku.hk | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Cheung, KSM: cks634@hku.hk | - |
dc.identifier.email | Hui, WHR: huirex@connect.hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@gastro.hk | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Mak, LY=rp02668 | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Cheung, KSM=rp02532 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | abstract | - |
dc.identifier.hkuros | 322887 | - |
dc.identifier.hkuros | 327158 | - |
dc.identifier.volume | 15 | - |
dc.identifier.issue | Suppl. 1 | - |
dc.identifier.spage | S52 | - |
dc.identifier.epage | S53 | - |
dc.publisher.place | India | - |
dc.identifier.partofdoi | 10.1007/s12072-021-10213-7 | - |